morphic
announces
presentation
new
data
supporting
development
ueg
week
virtual
validate
physiologically
relevant
assay
used
phase
studies
measure
receptor
occupancy
α
β
inhibitor
α
β
integrin
development
treat
inflammatory
bowel
waltham
globe
newswire
morphic
therapeutic
nasdaq
morf
biopharmaceutical
company
developing
new
generation
oral
integrin
therapies
treatment
serious
chronic
diseases
today
announced
poster
presentation
new
preclinical
data
ueg
week
virtual
meeting
new
data
support
profile
potent
selective
orally
available
small
molecule
inhibitor
integrin
α
β
establish
assays
key
clinically
relevant
biomarkers
ongoing
phase
trial
clinical
development
oral
small
molecule
inhibitor
α
β
integrin
treatment
inflammatory
bowel
disease
ibd
initial
focus
ulcerative
colitis
uc
data
presented
ueg
week
expand
results
previous
studies
demonstrating
high
selectivity
integrin
target
α
β
ex
vivo
human
translational
biomarkers
stated
bruce
rogers
phd
chief
scientific
officer
morphic
importantly
data
morphic
validated
physiologically
relevant
assay
measure
α
β
receptor
occupancy
human
whole
blood
important
pharmacodynamic
marker
studied
ongoing
phase
trial
focused
translation
promising
preclinical
data
clinical
results
phase
study
details
poster
presentation
ueg
title
translational
biomarkers
selective
oral
small
molecule
α
β
inhibitor
presenter
maloy
mangada
phd
associate
director
translational
sciences
morphic
therapeutic
inc
contributors
maloy
mangada
naresh
redhu
terence
moy
ali
hussain
vinod
yadav
lin
brianna
bannister
raegan
bonesteel
sarah
gelais
dan
cui
andrew
sullivan
liangsu
wang
alex
lugovskoy
kwangsoo
kim
jessica
pondish
peter
traber
peter
linde
dawn
troast
cheng
zhong
kristopher
hahn
matthew
bursavich
jamie
wong
blaise
lippa
bruce
rogers
adrian
ray
ueg
poster
available
morphic
website
investor
page
morphic
developing
selective
oral
small
molecule
inhibitor
α
β
integrin
patients
inflammatory
bowel
disease
ibd
α
β
clinically
validated
target
treatment
ibd
success
approved
injectable
antibody
therapeutic
vedolizumab
designed
block
interactions
α
β
surface
lymphocytes
mucosal
endothelial
cell
ligand
substantially
reducing
lymphocyte
migration
bloodstream
intestinal
mucosal
tissues
causing
inflammation
associated
ibd
inflammatory
bowel
disease
inflammatory
bowel
disease
ibd
comprises
several
autoimmune
conditions
characterized
chronic
inflammation
gastrointestinal
tract
ulcerative
colitis
crohn
disease
two
common
types
ibd
ulcerative
colitis
inflammation
limited
lining
colon
whereas
crohn
disease
inflammation
segmentally
affect
part
gastrointestinal
tract
entire
thickness
bowel
wall
symptoms
conditions
include
persistent
diarrhea
abdominal
pain
rectal
bleeding
weight
loss
fatigue
approved
medications
may
adequately
control
symptoms
many
patients
develop
complications
require
surgical
removal
colon
rectum
according
report
crohn
colitis
foundation
november
approximately
people
living
ulcerative
colitis
crohn
disease
united
states
new
cases
diagnosed
per
year
among
fda
approved
therapies
use
moderate
severe
ibd
vedolizumab
injectable
monoclonal
antibody
inhibitor
integrin
α
β
morphic
therapeutic
morphic
therapeutic
biopharmaceutical
company
developing
new
generation
oral
integrin
therapies
treatment
serious
chronic
diseases
including
autoimmune
cardiovascular
metabolic
diseases
fibrosis
cancer
collaboration
abbvie
janssen
schrödinger
morphic
advancing
pipeline
discovery
activities
using
proprietary
mint
technology
platform
leverages
company
unique
understanding
integrin
structure
biology
information
visit
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
including
limited
mint
platform
ability
discover
drug
candidates
morphic
plans
develop
commercialize
oral
integrin
therapeutics
execution
phase
clinical
trial
designed
expectations
safety
efficacy
timing
ability
commence
complete
clinical
studies
obtain
regulatory
approvals
candidates
development
ability
treat
inflammatory
bowel
disease
related
indications
statements
including
words
believe
plan
continue
expect
develop
signal
potential
ongoing
statements
future
tense
statements
statements
involve
risks
uncertainties
well
assumptions
fully
materialize
prove
incorrect
could
cause
results
differ
materially
expressed
implied
statements
statements
subject
risks
uncertainties
may
cause
morphic
actual
activities
results
differ
significantly
expressed
statement
including
risks
uncertainties
press
release
risks
set
forth
filings
securities
exchange
commission
including
morphic
partner
ability
develop
obtain
regulatory
approval
commercialize
product
candidate
morphic
ability
protect
intellectual
property
potential
impact
pandemic
sufficiency
cash
cash
equivalents
investments
fund
operations
statements
speak
date
hereof
morphic
specifically
disclaims
obligation
update
statements
reasons
actual
results
might
differ
whether
result
new
information
future
events
otherwise
except
required
law
contacts
morphic
therapeutic
chris
erdman
media
contact
nichole
sarkis
ten
bridge
communications
nichole
